To recover your password please fill in your email address
Please fill in below form to create an account with us
Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation Among Patients with G13D Mutation.
|
Trial Summary: |
Randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS wild-type or G13D mutation |
|
Supported By: |
Merck Serono |
|
Eligibility: |
Patients with metastatic colorectal cancer with either KRAS WT or KRAS G13D mutation |
|
Registration ID: |
ACTRN12612000901808 |
|
Participation: |
International |
|
Australian Lead Group: |
AGITG |
|
Status: |
Closed |
|
Activation Date: |
01/11/12 |
|
Chairs: |
Eva Segelov (Australia), Jeremy Shapiro (Australia) |
|
Contact: |